Features

David Rosenberg: The last year of the cycle

2018 is starting to look a lot like 1988, 1999 and 2006, reckons investment guru David Rosenberg. Investors should make the most of the next 12 months.

As we enter 2018, the "backdrop is eerily similar to 1988, 1999 and 2006", warns David Rosenberg, chief economist and strategist at Canadian money manager Gluskin Sheff. "And what we know about each of those years is that the one that followed was the last of the cycle." In short, investors should enjoy the next 12 months, because this bull market and economic expansion is on its last legs.

"I am far from advocating that anyone head for the hills or move totally into cash just yet," Rosenberg cautions. But it's time to invest more defensively. So "focus on companies with strong balance sheets" and "low refinancing risks". Look for "earnings quality and predictability", and don't be surprised if long-term bond yields "go even lower" than they are today. One problem is that stocks particularly in the US are pricing in "very little in the way of anything possibly going wrong".

Another risk, reckons Rosenberg, is that the departure of Federal Reserve chair Janet Yellen as well as several other key Fed members leaves a "relatively inexperienced" US central bank team trying to unwind quantitative easing. That suggests that a policy error is a very real possibility. "The history of new Fed chairs is that they overtighten and we know what history says about the consequences economic, financial or both."

On the bright side, Rosenberg is far more excited about Japan than he is about the US. Corporate governance is improving and many companies have the spare cash to spend on boosting dividends and share buybacks. Better yet, it's relatively cheap. "Japan is one of the few markets globally that is not trading at premium multiples relative to its history and is an under-owned market both globally and locally."

Recommended

How long can the good times roll?
Economy

How long can the good times roll?

Despite all the doom and gloom that has dominated our headlines for most of 2019, Britain and most of the rest of the developing world is currently en…
19 Dec 2019
Big Pharma deserves its reward for coming up with Covid-19 vaccines
Biotech stocks

Big Pharma deserves its reward for coming up with Covid-19 vaccines

Calls to restrain drug companies' profits from making Covid-19 vaccines are misplaced and would do more harm than good, says Matthew Lynn
29 Nov 2020
Bill Ackman: beware of short-term market volatility
Investment gurus

Bill Ackman: beware of short-term market volatility

Bill Ackman, founder of the Pershing Square hedge fund, is upbeat on prospects for markets in 2021, but is worried about short-term volatility as coro…
27 Nov 2020
More good news as AstraZeneca finds a third Covid vaccine
Biotech stocks

More good news as AstraZeneca finds a third Covid vaccine

Another week, another Covid-19 vaccine. This one from AstraZeneca and Oxford University is homegrown and ready to roll out fast. Matthew Partridge rep…
26 Nov 2020

Most Popular

The next 20 years: five new technologies on the horizon
Global Economy

The next 20 years: five new technologies on the horizon

What will everyday life be like in two decades’ time? Matthew Partridge peers into his crystal ball.
12 Nov 2020
This week’s rally in value stocks is just the beginning
Value investing

This week’s rally in value stocks is just the beginning

The arrival of a vaccine this week saw huge gains in the markets and investors switching out of big-tech growth stocks and into “value” stocks in more…
13 Nov 2020
Share tips of the week
Share tips

Share tips of the week

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
13 Nov 2020